Protein-bound solute removal during extended multipass versus standard hemodialysis by Eloot, Sunny et al.
Eloot et al. BMC Nephrology  (2015) 16:57 
DOI 10.1186/s12882-015-0056-yRESEARCH ARTICLE Open AccessProtein-bound solute removal during extended
multipass versus standard hemodialysis
Sunny Eloot1*, Wim Van Biesen1, Mette Axelsen2, Griet Glorieux1, Robert Smith Pedersen3ˆ and James Goya Heaf4Abstract
Background: Multipass hemodialysis (MPHD) is a recently described dialysis modality, involving the use of small
volumes of dialysate which are repetitively recycled. Dialysis regimes of 8 hours for six days a week using this
device result in an increased removal of small water soluble solutes and middle molecules compared to standard
hemodialysis (SHD). Since protein-bound solutes (PBS) exert important pathophysiological effects, we investigated
whether MPHD results in improved removal of PBS as well.
Methods: A cross-over study (Clinical Trial NCT01267760) was performed in nine stable HD patients. At midweek a
single dialysis session was performed with either 4 hours SHD using a dialysate flow of 500 mL/min or 8 hours
MPHD with a dialysate volume of 50% of estimated body water volume. Blood and dialysate samples were taken
every hour to determine concentrations of p-cresylglucuronide (PCG), hippuric acid (HA), indole acetic acid (IAA),
indoxyl sulfate (IS), and p-cresylsulfate (PCS). Dialyser extraction ratio, reduction ratio, and solute removal were
calculated for these solutes.
Results: Already at 60 min after dialysis start, the extraction ratio in the hemodialyser was a factor 1.4-4 lower with
MPHD versus SHD, resulting in significantly smaller reduction ratios and lower solute removal within a single
session. Even when extrapolating our findings to 3 times 4 h SHD and 6 times 8 h MPHD per week, the latter
modality was at best similar in terms of total solute removal for most protein-bound solutes, and worse for the
highly protein-bound solutes IS and PCS. When efficiency was calculated as solute removal/litre of dialysate used,
MPHD was found superior to SHD.
Conclusion: When high water consumption is a concern, a treatment regimen of 6 times/week 8 h MPHD might
be an alternative for 3 times/week 4 h SHD, but at the expense of a lower total solute removal of highly
protein-bound solutes.
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To overcome the non-physiological characteristics of
standard 3 times/week 4 hour in-centre hemodialysis,
alternative dialysis regimens are being developed, aim-
ing to reduce labour costs and patient burden, and
increase patient comfort and solute removal [1-14]. In
addition, production of dialysate is being recognized as
having an important financial and ecological cost,
which is likely to even increase in the future [15].
There is an increasing interest in these alternative renal* Correspondence: sunny.eloot@ugent.be
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unless otherwise stated.replacement therapies, whereby either duration of a single
session (extended dialysis) [4,7,11,14], the frequency per
week (frequent dialysis) [1,2,6,8,9,13] or a combination
thereof [3,12] are different from standard 3 times/week
dialysis. For most of these settings, regular dialysis moni-
tors are used, with online production of dialysate. Some
alternative approaches have been proposed, whereby
either dialysate is prepared as a batch [16-18], or is avail-
able in industrially prepared bags [19].
Recently, multipass hemodialysis (MPHD) was de-
scribed as a feasible, economic and ecologic alternative
to deliver home hemodialysis [20]. A regime of daily
nocturnal dialysis eight hours six times a week, using a
dialysate bath of one half of the calculated total bodyhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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alysate flow of 500 mL/min, while blood flow is conven-
tional (>200 mL/min) was proposed as treatment
paradigm. Obvious advantages are the ease of use, and
the low water consumption, making the technique ideal
for home hemodialysis. Using this technique, a signifi-
cantly higher weekly removal was obtained for small
water soluble solutes and for middle molecules like β2-
microglobulin, as compared to 3 times 4 h standard
hemodialysis (SHD) [20]. Since higher middle molecule
removal has been linked to reduced mortality [21], and
due to the limited dialysate consumption, MPHD seems
to be a very promising technique for performing (port-
able) home hemodialysis.
Protein-bound solutes are known as difficult to re-
move by conventional hemodialysis as the ligand pro-
teins often have a molecular weight above or at the
borderline of the cut-off of currently used high flux dia-
lysis membranes. This lack of adequate removal may
have important clinical consequences, since several
protein-bound solutes have been linked to progression
of renal failure, inflammation, vascular disease, and
mortality [22-35].
The present study was set up to investigate removal of




The patients and methods have been described in a pre-
vious publication [20]. Ten stable HD patients, all re-
ceiving standard in-centre HD three times per week
were included in the original study, but, due to sample
corruption, only nine are included in the present study.
Exclusion criteria were: age less than 18 years, psychi-
atric disease, ultrafiltration requirement more than 4 L
per session, possibility of pregnancy and severe comor-
bidity. Prior to the study, catheter/fistula recirculation
was excluded using the indicator dilution technique and
the Krivitski method (HD 01 plus, Transonic Systems,
Ithaca, New York State). All patients gave written in-
formed consent according to the Helsinki II declaration.
The protocol was approved by the local ethics commit-
tee ‘Videnskabsetiske Komité for Hovedstads Region’
(identification number H-2-2009-082) and registered on
ClinicalTrials.gov (identification number NCT01267760).
Study design
Each patient was studied twice with a one week interval.
The patients used either the Polyflux 170H (3 patients)
or Polyflux 210H with a surface area of 1.7 and 2.1 m2,
respectively (Gambro, Lund, Sweden) for both sessions.
The reference treatment was standard hemodialysis
(SHD) lasting 4 hours, with a dialysate flow of 500 mL/min. The dialysate was continuously collected in a
chamber placed on electronic weighing scales. A blender
was placed in the chamber to assure adequate mixing
before sampling.
The alternative treatment was multipass hemodialysis
(MPHD) using a dialysate chamber with a volume corre-
sponding to 50% of the patient’s total body water
(TBW), which was estimated as either 55% (female) or
60% (male) of dry weight. One patient, with a body
weight of 111 kg and an estimated TBW of 66 L was
only treated with 30.4 L due to the limitations of the di-
alysate chamber. The dialysate was prepared by the AK-
200 dialysis machine (Gambro, Lund, Sweden), and was
identical for both treatments. With MPHD, dialysate
was recirculated via the chamber which was placed on
electronic scales, and in which an oscillation mechanism
was installed to assure optimal mixing. Two pumps con-
trolled dialysate inflow (500 mL/min - UF/2) and out-
flow (500 mL/min + UF/2), and thus ultrafiltration (UF).
Dialysate temperature was set at 36-37°C at the dialyser
inlet, and was continuously registered.
Fractionated heparin was used as anticoagulation, at
the patient’s usual dose (at the start of SHD and
MPHD). After 4 hours MPHD a new similar bolus was
administered.
Sampling and analysis
Blood samples were collected from the inlet blood line
at the start and at hourly intervals. In addition, one
blood sample was taken from the blood outlet line at
60 min to obtain the dialyser extraction ratio. Blood
samples were immediately centrifuged at 3000 rpm, after
which the plasma was stored at −80°C until batch ana-
lysis. From the dialysate chamber, dialysate was sampled
hourly and stored at −80°C.
Different protein-bound solutes were determined by
high performance liquid chromatography (HPLC): p-
cresylglucuronide (PCG) (molecular weight MW:284 Da,
protein binding PB ~ 10%), hippuric acid (HA - 179 Da -
PB ~ 50%), indole acetic acid (IAA - 175 Da - PB ~ 65%),
indoxyl sulfate (IS - 213 Da - PB ~ 90%), p-cresylsulfate
(PCS - 187 Da - PB ~ 95%). To determine the total con-
centration, serum samples were first deproteinized by
heat denaturation [36] before HPLC analysis. IS and
IAA (excitation λex: 280 nm; emission λem: 340 nm) and
PCS and PCG (λex: 265 nm; λem: 290 nm) were deter-
mined by fluorescence analysis, and HA by UV detec-
tion at 245 nm [37]. Free fractions were determined
according to Fagugli et al. [37] and serum total protein
(TP) was analysed according to standard methods.
Calculations
Reduction ratio (RR - %) of solutes was defined as a
function of predialysis (Cpre) and postdialysis concentra-
tions (Cpost) of samples collected from the inlet blood line:
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During 8 h MPHD, RR was also calculated for the 0-
240 min and the 240-480 min dialysis interval.
The dialyser extraction ratio (ER - %) was calculated
as the relative change in concentration from the dialyser
inlet (Cinlet) towards the outlet (Coutlet):Figure 1 Serum concentrations at different time points during standard he
(diamonds - dotted line) for p-cresylglucuronide (PCG -panel A), hippuric a
(IS - panel D), and p-cresylsulfate (PCS - panel E). *P < 0.05 MPHD versus SHER %ð Þ ¼ Cinlet−Coutlet
Cinlet
⋅100 ð2Þ
Total solute removal (TSR - mg) at time point t was
calculated from dialysate concentration in the chamber
at that time point, and multiplied by either the volume
of spent dialysate at time point t (SHD) or the dialysate
volume in the chamber (MPHD). Total solute removal
on weekly basis was calculated from TSR as measuredmodialysis SHD (squares - full line) and multipass hemodialysis MPHD
cid (HA - panel B), indole acetic acid (IAA - panel C), indoxyl sulfate
D. †P = 0.053 MPHD versus SHD.
Table 1 Reduction ratios (%) for different protein-bound
solutes in SHD and MPHD
Solute SHD MPHD
0-240 min 0-240 min 240-480 min 0-480 min
Total PCG 81 ± 7 51 ± 5 9 ± 9† 55 ± 6*†
Total HA 68 ± 10 42 ± 7 1 ± 37† 43 ± 16*
Total IAA 46 ± 8 25 ± 5 9 ± 13† 32 ± 8*
Total IS 41 ± 11 14 ± 6 10 ± 12 23 ± 11*†
Total PCS 37 ± 9 10 ± 9 6 ± 18 16 ± 15*
Free PCG 84 ± 5 51 ± 5 10 ± 10† 56 ± 6*†
Free HA 78 ± 8 45 ± 11 −5 ± 38† 44 ± 16*
Free IAA 67 ± 28 33 ± 13 8 ± 21† 39 ± 18*
Free IS 59 ± 17 −7 ± 33 7 ± 43 −2 ± 55*
Free PCS 74 ± 11 −1 ± 44 7 ± 39 7 ± 51*
SHD: standard hemodialysis; MPHD: multipass hemodialysis; PCG:
p-cresylglucuronide; HA: hippuric acid; IAA: indole acetic acid; IS: indoxyl sulfate;
PCS: p-cresylsulfate.
*P < 0.05 versus SHD; †P < 0.05 versus MPHD0-240min.
Table 2 Extraction ratios (%) at 60 min during SHD and
MPHD for total and free fractions of different
protein-bound solutes
Solute SHD MPHD SHD/MPHD
Total PCG 73 ± 15 53 ± 8* 1.4
Total HA 54 ± 10 31 ± 19* 1.7
Total IAA 29 ± 8 16 ± 8* 1.8
Total IS 13 ± 5 5 ± 5* 2.9
Total PCS 11 ± 6 3 ± 5* 3.9
Free PCG 78 ± 10 55 ± 9* 1.4
Free HA 65 ± 11 43 ± 8* 1.5
Free IAA 49 ± 23 31 ± 12* 1.6
Free IS 36 ± 9 17 ± 10* 2.1
Free PCS 38 ± 15 15 ± 10* 2.5
SHD: standard hemodialysis; MPHD: multipass hemodialysis; PCG:
p-cresylglucuronide; HA: hippuric acid; IAA: indole acetic acid; IS: indoxyl sulfate;
PCS: p-cresylsulfate.
*P < 0.05 versus SHD.
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dialysis frequency per week.
Protein-bound solute concentrations at time point t
were corrected for hemoconcentration by a factor (F)
based on TP concentration predialysis versus time point
t: F = TPpre/TPt. Likewise, dialyser outlet concentration
(Coutlet) was corrected by F = TPinlet/TPoutlet.
Statistical analysis
Data are expressed as mean ± SD assuming normally
distributed populations. Statistical analyses were car-
ried out using the parametric t-test for paired samples.
A P ≤ 0.05 was considered to be statistically significant.
All statistical analyses were performed using SPSS Sta-
tistics 21 (SPSS Inc, Chicago, IL) for Windows (Micro-
soft Corp, Redmond,WA).
Results
The nine included patients (female n = 3) were 63.4 ±
12.7 years old and spent 7.1 ± 4.4 years on dialysis. Renal
diagnoses were: hypertensive nephropathy (n = 3), poly-
cystic renal disease (n = 1), glomerulonephritis (n = 1),
chronic interstitial nephropathy (n = 1), and unknown
(n = 3). Five patients had a residual daily diuresis of
more than 300 mL/day. Patients dry weight was 79.8 ±
19.4 kg, resulting in a calculated TBW of 46.5 ± 11.2 kg.
Accordingly, MPHD dialysate volume was 22.9 ± 5.0 L
(range 13.8 to 30.4 L). Blood flow was 279 ± 43 mL/min
during SHD and 279 ± 41 mL/min during MPHD (N.S.).
Figure 1 illustrates the variation in serum concentra-
tion during SHD (squares - full line) and MPHD (dia-
monds - dotted line) for p-cresylglucuronide (PCG),
hippuric acid (HA), indole acetic acid (IAA), indoxyl
sulfate (IS), and p-cresylsulfate (PCS). Serum concentra-
tions at start of the dialysis session were not different
between both modalities in the individual patients (N.S.).
The large standard deviations indicate important inter-
patient variability in serum concentrations of these sol-
utes. Nevertheless, it was in all patients consistently ob-
served that concentration reductions were much smaller
with 8 h MPHD as compared to 4 h SHD. In addition, it
is noteworthy that during the second half of the 8 h
MPHD, nearly no further change in concentration reduc-
tion was observed (Table 1).
Already at 60 min after dialysis start, a huge difference
is observed between the extraction ratio for total and
free fractions during SHD and MPHD, due to the recir-
culation in the latter modality (Table 2). Extraction in
the hemodialyser for total concentrations of protein-
bound solutes is a factor 1.4-1.8 (PCG, HA, IAA) and
3–4 (IS, PCS) larger with SHD as compared to MPHD,
while for the free fractions of these solutes, it is a factor
1.4-1.6 (PCG, HA, IAA) and 2.1-2.5 (IS, PCS). Hence,
there is an inverse correlation between extraction ratioand percentage protein binding in both SHD (R = −0.98)
and MPHD (R = −0.99), but extraction of highly bound
solutes like IS and PCS is even more hampered in
MPHD compared to SHD.
Figure 2 clearly indicates that the cumulative total sol-
ute removal (TSR) with MPHD versus SHD is, for all
studied solutes, much smaller. Of note, TSR seems to
saturate after 4 h MPHD. The normalized TSR for the
amount of used dialysate was a factor 3–3.9 (PCG, HA,
IAA) and 1.8-1.9 (IS, PCS) larger with MPHD as
compared to SHD (Table 3), indicating the relative effi-
ciency of the MPHD modality with regard to water use.
Figure 2 Cumulative total solute removal (TSR) at different time points during standard hemodialysis SHD (squares - full line) and multipass
hemodialysis MPHD (diamonds - dotted line) for p-cresylglucuronide (PCG - panel A), hippuric acid (HA - panel B), indole acetic acid (IAA - panel C),
and indoxyl sulfate (IS - panel D), p-cresylsulfate (PCS - panel E). *P < 0.05 MPHD versus SHD.
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extrapolated to a weekly basis, the absolute TSR during
6 times 8 h MPHD versus 3 times 4 h SHD was larger
for PCG and IAA (Table 4), not different for HA and
smaller for IS and PCS. For 6 times 4 h MPHD versus 3
times 4 h SHD, TSR is only larger for PCG while
smaller for IS and PCS, and for 6 times 2 h MPHD ver-
sus 3 times SHD, TSR is significantly smaller for HA,
IS, and PCS.Discussion
In this cross-over study comparing 4 h standard
hemodialysis (SHD) with 8 h multipass hemodialysis
(MPHD), concentration reduction and total solute
removal were assessed for the protein-bound solutes
p-cresylglucuronide (PCG), hippuric acid (HA), indole
acetic acid (IAA), indoxyl sulfate (IS), and p-cresylsulfate
(PCS). We found that already at 60 min after dialysis
start, the extraction ratio in the hemodialyser was a
Table 3 Total solute removal per litre used dialysate (mg/L) and the ratio of total solute removal during MPHD versus
SHD
Solute SHD MPHD MPHD0‐240SHD
MPHD0‐480
SHD
0-240 min 0-240 min 0-480 min
Total PCG 1.29 ± 1.22 4.22 ± 3.57 4.71 ± 3.93*† 3.6 ± 1.4 3.9 ± 1.7
Total HA 5.35 ± 5.39 10.4 ± 9.2 12.5 ± 11.3*† 2.7 ± 1.3 3.0 ± 1.0
Total IAA 0.22 ± 0.27 0.52 ± 0.44 0.57 ± 0.50 3.4 ± 1.5 3.7 ± 1.9
Total IS 1.29 ± 0.79 2.43 ± 1.72 2.54 ± 1.76* 1.8 ± 0.6 1.8 ± 0.7
Total PCS 0.83 ± 0.50 1.60 ± 0.87 1.56 ± 0.92* 2.0 ± 0.9 1.9 ± 0.9
SHD: standard hemodialysis; MPHD: multipass hemodialysis; PCG: p-cresylglucuronide; HA: hippuric acid; IAA: indole acetic acid; IS: indoxyl sulfate;
PCS: p-cresylsulfate.
*P < 0.05 versus SHD; †P < 0.05 versus MPHD0-240min.
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lower reduction ratios and total solute removal. When
TSR was calculated per litre of dialysate spent, MPHD
appeared to be superior.
It was recently demonstrated that MPHD resulted in
superior removal of small and middle molecular weight
solutes when applied as 6 times/week 8 h dialysis, an ef-
fect that was already demonstrated previously using an-
other batch system (Genius®, Fresenius Medical Care)
[4]. Our current results add to this knowledge that
MPHD applied in this regimen results in equal total sol-
ute removal for light and moderately protein-bound sol-
utes, but lower removal for highly protein-bound solutes
as compared to standard 3 times weekly hemodialysis.
Most likely, this can be explained by the fact that only the
free solute can pass across the membrane. As the serum
concentration of free solute is rather low, and as the di-
alysate is recycled, there is a rapid equilibration between
the concentrations of the free solute in the serum and in
the dialysate. As a result, replenishment of the pool of free
toxin in the serum, either by loosening from the protein
or by rebound from other compartments, has no effect on
solute removal, as the diffusive gradient with the dialysate
is lacking. Indeed, we observe (Figure 1) that after someTable 4 Weekly total solute removal (mg) for 3 times 4 h
SHD, 6 times 2 h MPHD, 6 times 4 h MPHD, and 6 times
8 h MPHD for different protein-bound solutes
Solute 3x4 h SHD 6x2 h MPHD 6x4 h MPHD 6x8 h MPHD
Total PCG 480 ± 458 498 ± 452 655 ± 592* 729 ± 650*†
Total HA 1985 ± 2010 1338 ± 1296* 1738 ± 1688 2104 ± 2096†
Total IAA 83 ± 101 69 ± 70 89 ± 90 98 ± 105*
Total IS 478 ± 291 308 ± 232* 388 ± 314* 406 ± 320*
Total PCS 306 ± 183 199 ± 112* 246 ± 148* 241 ± 155**
SHD: standard hemodialysis; MPHD: multipass hemodialysis; PCG:
p-cresylglucuronide; HA: hippuric acid; IAA: indole acetic acid; IS: indoxyl
sulfate; PCS: p-cresylsulfate.
*P < 0.05 versus 3x4 h SHD; **P = 0.57 versus 3x4 h SHD; †P < 0.05 versus
6x4 h MPHD.hours of dialysis, there is a plateau of the concentration in
the dialysate, and accordingly, a significantly lower extrac-
tion ratio in the hemodialyser is observed already after
60 min. After this, no further solute removal is observed.
The timing of this plateau phase comes more early as the
solute is more strongly protein-bound. Extending the dia-
lysis session is accordingly of no use to increase solute re-
moval of protein-bound toxins when small volumes of
dialysate are recycled.
For middle molecular structures such as β2-micro-
globulin, this diffusive transport over the dialysis mem-
brane is much slower, so the equilibration/saturation is
also occurring at a slower rate. An increase of dialysis
time from 4 to 8 hours, maintaining the same amount
of processed blood and dialysate, previously demon-
strated a 81% higher β2-microglobulin removal, a
phenomenon that was much less pronounced (26-36%
increase) for the small water soluble solutes urea and
creatinine [4]. This effect can be attributed to the slow
transport of β2-microglobulin between the extraplas-
matic and plasmatic compartment [38,39], resulting in
a substantial rebound after conventional and short
hemodialysis [40]. During extended dialysis, the solute
is allowed more time to shift between compartments.
Accordingly, extending the dialysis session allows the
serum pool of the middle molecule to be replenished
from other compartments, resulting in an increase in
solute removal even when recycling the dialysate, as
demonstrated previously [20].
A limitation of our study might be the mathematical ex-
trapolation of the removal during a single session to the
removal on weekly basis. Theoretically, since predialysis
concentrations of toxins can be decreased in frequent dia-
lysis, solute removal could be overestimated with frequent
MPHD. However, as we are dealing with protein-bound
solutes, only the free fraction can be eliminated during the
dialysis session such that total removal is very low. Hence,
it is likely that this free fraction is completely restored dur-
ing the interdialytic interval, which was also found by
Fagugli et al. investigating removal of protein-bound
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compared to standard hemodialysis (3 times weekly
4 hours), even with a regular dialysis monitor and di-
alysate flow, so that saturation of dialysate could not
play a role [37].
It could be hypothesized that in order to increase sol-
ute removal of protein-bound toxins, one needs to ex-
tend total weekly treatment time, and use sufficiently
high ratio of dialysate to blood flow. A recent kinetic
analysis supported this hypothesis [41]. If it is intended
to use recycling of dialysate, an absorbent should be
added to the dialysate system to keep the concentration
of the free fraction of protein-bound solutes as low as
possible.
Although it appears that MPHD is less suitable than
SHD to remove protein-bound solutes, the advantage of
MPHD is mainly the relatively higher amount of solute
removed per litre of dialysate (Table 3). This makes the
multipass system a suitable alternative to apply in the
setting of daily extended dialysis at home [42], where
the classical setup implies substantial technical modifi-
cations and results in a high consumption of water and
electricity. The economy in water consumption is 33%
(240 L/week versus 360 L/week), as more frequent dia-
lysis is needed. Whereas this seems an impressive sav-
ing, we need to realize that water consumption is with
4-11% only a limited part of the carbon foot print of
dialysis treatment, as compared to 35.7% for pharma-
ceuticals and 23.4% for medical equipment.
Conclusion
MPHD appears to have some interesting features for
use in the home setting, and results in more efficient
use of dialysate. However, the currently proposed regi-
men of 6 times/week 8 hours seems to have no advan-
tage over 3 times/week SHD in terms of removal of
protein-bound solutes.
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